Compare Danaher Corporation (DHR) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Plby Group Inc — how do they compare? Danaher Corporation trades at $200.72 (market cap $140.88B), while Plby Group Inc trades at $1.13 (market cap $136.40M). The key difference: Danaher Corporation is far larger — about 1032.8× Plby Group Inc's market cap, and Danaher Corporation pays a 0.8% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| DHR | PLBY | |
|---|---|---|
Market Cap | $140.88B | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $2.71 |
52-Week Low | $161.91 | $1.14 |
Enterprise Value | $153.66B | $284.21M |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
PLBY trades at $1.17, up 0.86% today, but remains in a bearish technical trend. The company reported Q1 2026 revenue of $30.2 million with a narrowed net loss of $4.0 million, showing operational improvement. Recent news includes inclusion in Russell indexes and a major share repurchase. Despite negative ROE and high debt, analyst sentiment is positive with 75% buy ratings.
The outlook hinges on continued EBITDA growth and debt management. Opportunities include brand licensing momentum and cost controls. Key risks are persistent net losses, high leverage, and competitive pressures. Investors should weigh analyst optimism against fundamental challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
